TipRanks
Advertisement
Advertisement

ACIU Stock Latest News

AC Immune Adds Tom Graney to Board Following Extraordinary General Meeting
Company AnnouncementsAC Immune Adds Tom Graney to Board Following Extraordinary General Meeting
11d ago
6K
ACIU
Fein Reiterates Buy on AC Immune as VacSYn Phase 2 Data Validate Platform; $12 Price Target Maintained
PremiumRatings
Fein Reiterates Buy on AC Immune as VacSYn Phase 2 Data Validate Platform; $12 Price Target Maintained
19d ago
ACIU
AC Immune Posts Strong Week-100 Phase 2 Data for Parkinson’s Vaccine ACI-7104
PremiumCompany Announcements
AC Immune Posts Strong Week-100 Phase 2 Data for Parkinson’s Vaccine ACI-7104
20d ago
6K
ACIU
AC Immune announces Phase 2 trial of ACI-7104 met primary endpoints
PremiumThe Fly
AC Immune announces Phase 2 trial of ACI-7104 met primary endpoints
20d ago
ACIU
AC Immune Calls October EGM to Add Veteran Biopharma Financier Tom Graney to Board
PremiumCompany Announcements
AC Immune Calls October EGM to Add Veteran Biopharma Financier Tom Graney to Board
1M ago
6K
ACIU
AC Immune’s New Phase 1 NLRP3 Trial Puts Inflammation Strategy in Focus
PremiumCompany AnnouncementsAC Immune’s New Phase 1 NLRP3 Trial Puts Inflammation Strategy in Focus
1M ago
ACIU
Stifel’s Thomas Shrader Reiterates Buy on AC Immune, Citing Diversified Neuroscience Pipeline, Promising NLRP3 Data, and Strong Cash Runway
Premium
Ratings
Stifel’s Thomas Shrader Reiterates Buy on AC Immune, Citing Diversified Neuroscience Pipeline, Promising NLRP3 Data, and Strong Cash Runway
2M ago
ACIU
AC Immune posts positive first‑in‑human data for NLRP3 inhibitor ACI‑19764
Premium
Company Announcements
AC Immune posts positive first‑in‑human data for NLRP3 inhibitor ACI‑19764
2M ago
6K
ACIU
AC Immune receives fast track designation, clearance for ACI-7104 IND
PremiumThe Fly
AC Immune receives fast track designation, clearance for ACI-7104 IND
2M ago
ACIU
AC Immune Wins FDA Fast Track for ACI-7104 in Early Parkinson’s Disease
PremiumCompany Announcements
AC Immune Wins FDA Fast Track for ACI-7104 in Early Parkinson’s Disease
2M ago
6K
ACIU
Analyst Reiterates Buy on AC Immune as 2H26 Catalysts Approach; Price Target Maintained at $12
PremiumRatings
Analyst Reiterates Buy on AC Immune as 2H26 Catalysts Approach; Price Target Maintained at $12
2M ago
ACIU
AC Immune Files First-Half 2026 Results and Corporate Update on Form 6-K
PremiumCompany Announcements
AC Immune Files First-Half 2026 Results and Corporate Update on Form 6-K
2M ago
6K
ACIU
AC Immune Unveils 12-Month Interim Data from ACI-24 Alzheimer’s Trial and Expands Takeda-Backed Program
PremiumCompany AnnouncementsAC Immune Unveils 12-Month Interim Data from ACI-24 Alzheimer’s Trial and Expands Takeda-Backed Program
4M ago
6K
ACIU
AC Immune announces interim data from first three cohorts of ABATE trial
Premium
The Fly
AC Immune announces interim data from first three cohorts of ABATE trial
4M ago
ACIU
AC Immune Shareholders Back Capital Band, Governance Slate and Pay Caps at June 11 AGM
Premium
Company Announcements
AC Immune Shareholders Back Capital Band, Governance Slate and Pay Caps at June 11 AGM
4M ago
6K
ACIU
AC Immune Secures $4 Million Goradia Foundation Grant to Extend Phase 2 Parkinson’s Trial
PremiumCompany Announcements
AC Immune Secures $4 Million Goradia Foundation Grant to Extend Phase 2 Parkinson’s Trial
4M ago
6K
ACIU
AC Immune presents new Phase 1 data on uptake of ACI-19626
PremiumThe Fly
AC Immune presents new Phase 1 data on uptake of ACI-19626
5M ago
ACIU
AC Immune Sets June AGM and Reshapes Leadership as Long-Serving CEO Retires
PremiumCompany Announcements
AC Immune Sets June AGM and Reshapes Leadership as Long-Serving CEO Retires
5M ago
6K
ACIU
AC Immune CEO and Co-Founder Andrea Pfeifer to Retire at June 11 AGM; Board Chair Martin Zügel Named Interim Chief
PremiumCompany Announcements
AC Immune CEO and Co-Founder Andrea Pfeifer to Retire at June 11 AGM; Board Chair Martin Zügel Named Interim Chief
5M ago
6K
ACIU
AC Immune reports Q1 EPS (15c), consensus (14c)
PremiumThe FlyAC Immune reports Q1 EPS (15c), consensus (14c)
6M ago
ACIU
AC Immune Triggers $12 Million Takeda Milestone as Final ABATE Cohort Starts in Alzheimer’s Trial
Premium
Company Announcements
AC Immune Triggers $12 Million Takeda Milestone as Final ABATE Cohort Starts in Alzheimer’s Trial
6M ago
6K
ACIU
AC Immune Posts Q1 2026 Update, Extends Cash Runway and Advances Neurodegeneration Pipeline
Premium
Company Announcements
AC Immune Posts Q1 2026 Update, Extends Cash Runway and Advances Neurodegeneration Pipeline
6M ago
6K
ACIU

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >